![]() Today’s announcement marks the first time that the FDA has authorized an MRTP. In making this assessment, the agency must consider, among other things, whether those who do not use tobacco products would start using the product and whether existing tobacco users who would have otherwise quit would switch to the modified risk product instead. This includes taking into account both users of tobacco products and persons who do not currently use tobacco products. In its review, the FDA generally must look at whether the applicant has demonstrated that the product – as actually used by consumers – will significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole. While all tobacco products pose risks, the MRTP pathway outlined in the 2009 Family Smoking Prevention and Tobacco Control Act allows companies to submit applications for the FDA to evaluate whether a tobacco product may be sold or distributed for use to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products. Should any information lead us to determine that the marketing of these products as posing less risk no longer benefits the health of the population as a whole, the agency would consider withdrawing this authorization.” “In addition to stringent restrictions to limit youth access and exposure to advertising, this time-limited authorization comes with a number of postmarket requirements that will allow us to keep a close watch on the marketplace. Anyone who does not currently use tobacco products, especially youth, should refrain from doing so,” said Acting FDA Commissioner Ned Sharpless, M.D. ![]() While we are authorizing these specific modified risk tobacco products, it’s important for the public to understand that all tobacco products - including these - pose risk. Our team of scientific experts examined these applications to ensure that the tobacco products meet the public health standards in the law. “Today’s action demonstrates the viability of the pathway for companies to market specific tobacco products as less harmful to consumers, but only following a thorough scientific evaluation by the FDA. The modified risk orders are product-specific and limited to five years. with a modified risk claim, it does not mean these products are safe or “FDA approved.” All tobacco products are potentially harmful and addictive, and those who do not use tobacco products should continue to refrain from their use. While today’s decision permits the eight General brand snus smokeless tobacco products to be sold in the U.S. ![]() In addition, the products’ packaging and advertising must also bear the warning statements required for all smokeless tobacco products. In an effort to help prevent youth access and exposure, the agency has also placed stringent advertising and promotion restrictions on the products, including a requirement to restrict advertising to adults. Today’s action further authorizes the manufacturer to market these specific products with the claim “Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” The FDA made this authorization after reviewing scientific evidence submitted by the company that supports this claim. ![]() sale without modified risk claims by the FDA in 2015 in response to filings of premarket tobacco applications (PMTAs). These products had previously been authorized for U.S. ![]() snus smokeless tobacco products sold under the “General” brand name. The authorizations are for eight Swedish Match USA, Inc. Food and Drug Administration announced today that, for the first time, it has authorized the marketing of products through the modified risk tobacco product (MRTP) pathway. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |